Modulation of NADPH oxidase activity by known uraemic retention solutes. (August 2014)

• Record Type: Journal Article
• Authors: Schulz, Anna Marta; Terne, Cindy; Jankowski, Vera; Cohen, Gerald; Schaefer, Mandy; Boehringer, Falko; Tepel, Martin; Kunkel, Desiree; Zidek, Walter; Jankowski, Joachim; European Uremic Toxin Work Group (EUTox)
• Is Part Of: European journal of clinical investigation. Volume 44:Number 8(2014:Aug.)
• Page Start: 802
• Page End: 811
• Publication Date: 2014-08
• Subjects: Pathology -- Periodicals; Medical research -- Periodicals; 616.075
• DOI: 10.1111/eci.12297
• Languages: English
• ISSNs: 0014-2972

Abstract

<abstract abstract-type="main" id="eci12297-abs-0001"> <title>Abstract</title> <sec id="eci12297-sec-0001" sec-type="section"> <title>Background</title> <p>Uraemia and cardiovascular disease appear to be associated with an increased oxidative burden. One of the key players in the genesis of reactive oxygen species (ROS) is nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. Based on initial experiments demonstrating a decreased inhibitory effect on NADPH oxidase activity in the presence of plasma from patients with CKD‐5D after dialysis compared with before dialysis, we investigated the effect of 48 known and commercially available uraemic retention solutes on the enzymatic activity of NADPH oxidase.</p> </sec> <sec id="eci12297-sec-0002" sec-type="section"> <title>Methods</title> <p>Mononuclear leucocytes isolated from buffy coats of healthy volunteers were isolated, lysed and incubated with NADH in the presence of plasma from healthy controls and patients with CKD‐5D. Furthermore, the leucocytes were lysed and incubated in the presence of uraemic retention solute of interest and diphenyleneiodonium chloride (DPI), an inhibitor of NADPH oxidase. The effect on enzymatic activity of NADPH oxidase was quantified within an incubation time of 120 min.</p> </sec> <sec id="eci12297-sec-0003" sec-type="section"> <title>Results</title> <p>Thirty‐nine of the 48 uraemic retention solutes tested had a significant decreasing effect on NADPH oxidase activity. Oxalate has been characterized as the strongest inhibitor of NADPH oxidase (90% of DPI inhibition). Surprisingly, none of the uraemic retention solutes we investigated was found to increase NADPH oxidase activity. Furthermore, plasma from patients with CKD‐5D before dialysis caused significantly higher inhibitory effect on NADPH oxidase activity compared with plasma from healthy subjects. However, this effect was significantly decreased in plasma from patients with CKD‐5D after dialysis.</p> </sec> <sec id="eci12297-sec-0004" sec-type="section"> <title>Conclusions</title> <p>The results of this study show that uraemic retention solutes modulated the activity of the NADPH oxidase. The results of this study might be the basis for the development of inhibitors applicable as drug in the situation of increased oxidative stress.</p> </sec> </abstract>